| Trial ID: | L7079 |
| Source ID: | NCT02235298
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Dapagliflozin Effects on Epicardial Fat
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02235298/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Metformin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Epicardial Fat Thickness, Epicardial fat thickness will be measured in millimeters by treating physician using echocardiography at Baseline, 12 weeks, 24 weeks, At Baseline, 12 weeks, 24 weeks | Secondary: Left Ventricular Mass (LVM), LVM will be measured in g/m\^2 by treating physician using echocardiography at baseline, Week 12 and Week 24, At Baseline, Week 12 and Week 24
|
| Sponsor/Collaborators: |
Sponsor: University of Miami | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-09
|
| Completion Date: |
2020-09-10
|
| Results First Posted: |
2021-02-16
|
| Last Update Posted: |
2021-02-16
|
| Locations: |
University of Miami, Miami, Florida, 33136, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02235298
|
